Searchable abstracts of presentations at key conferences in endocrinology

ea0063p545 | Diabetes, Obesity and Metabolism 2 | ECE2019

Lipid profile and cardiovascular risk in ankylosing spondylitis

Athanassiou Panagiotis , Tzanavari Aikaterini , Athanassiou Lambros , Dardavesis Theodoros , Ifigenia Kostoglou-Athanassiou

Introduction: Ankylosing spondylitis (AS) is a chronic systemic inflammatory disorder which affects the sacroiliac joints, the axial skeleton, peripheral joints as well as other organs. It develops in young adults causing significant mobility and functional disorders, with associated severe dysfunction or disability. Ankylosing spondylitis has serious adverse effects on the ability to work and quality of life. Biologic agents are used for the treatment of AS, this effect havin...

ea0049ep366 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

The effect of tocilizumab – an interleukin-6 receptor antagonist – on lipid levels in rheumatoid arthritis

Kostoglou-Athanassiou Ifigenia , Athanassiou Lambros , Tzanavari Aikaterini , Katsavouni Charoula , Kostopoulos Markos , Pantelidis Dimitrios , Athanassiou Panagiotis

Tocilizumab is an interleukin-6 receptor antagonist used in the treatment of rheumatoid arthritis (RA). It is known to induce remission and inhibit radiographic progression in RA. Tocilizumab may be administered either intravenously or subcutaneously. Its effect on lipid levels and the cardiovascular risk has not been fully investigated. The aim was to study the effect of tocilizumab i.v. on disease activity, lipid levels and cardiovascular risk in RA patients.<p class="ab...

ea0041gp39 | Bone &amp; Calcium Homeostasis | ECE2016

Drug holiday in osteoporosis. reducing side effects of long lasting treatments

Athanassiou Panagiotis , Pantazi Eleni , Skioti Ourania , Tzanavari Aikaterini , Kostoglou-Athanassiou Ifigenia

Introduction: Osteoporosis is a chronic and dangerous disease, as it may be silent and may express itself with a sudden catastrophic event, such as a fracture. Treatment of osteoporosis demands the use of potent pharmaceutical agents with long lasting effects. In particular, bisphosphonates, such as ibandronate, may be used. It has become evident that chronic treatment with anti-osteoporotic agents may reverse the course of the disease, patients having normal bone mineral dens...

ea0041ep131 | Bone &amp; Osteoporosis | ECE2016

Barrett’s esophagus and osteopenia: Report of a case

Athanassiou Panagiotis , Tzanavari Aikaterini , Spyridis Anestis , Kostopoulos Markos , Xanthakou Eleni , Kostoglou-Athanassiou Ifigenia

Introduction: Barrett’s esophagus is metaplasia in the cells of the lower end of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells. The disease is often related to gastroesophageal reflux and patients have pain necessitating chronic usage of proton pump inhibitors. Proton pump inhibitors have been associated with the development of low bone mineral dens...

ea0041ep641 | Endocrine tumours and neoplasia | ECE2016

Myelolipoma in a rheumatoid arthritis patient – report of a case

Tzanavari Aikaterini , Kostoglou-Athanassiou Ifigenia , Banti Theodota , Katsavouni Charoula , Xanthakou Eleni , Athanassiou Panagiotis

Introduction: Adrenal myelolipoma is an extremely rare benign adrenal tumor. Adrenal myelolipoma is characterized by the presence within the adrenal gland of mature adipose tissue and active bone marrow elements. Owing to their non-functional nature most cases are incidental, either at autopsy or through computer tomography scan. Occasionally the lesions attain a large size to become clinically apparent. Seropositive rheumatoid arthritis is a disorder affecting approximately 1...

ea0041ep655 | Endocrine tumours and neoplasia | ECE2016

Von Hippel-Lindau syndrome with musculoskeletal manifestations. report of a case

Athanassiou Panagiotis , Tzanavari Aikaterini , Pantazi Eleni , Spyridis Anestis , Kostoglou-Athanassiou Ifigenia

Introduction: Von Hippel-Lindau (VHL) syndrome is an inherited disorder characterized by the formation of tumors and cysts in diverse organ systems. Tumors may be malignant or benign and they tend to appear during young adulthood. Hemangioblastomas are characteristic of VHL syndrome.Aim: The aim was to describe the case of a patient with VHL syndrome presenting with musculoskeletal manifestations and multiple tumors.Case report: A ...

ea0037ep366 | Diabetes (pathiophysiology &amp; epitemiology) | ECE2015

Diabetes mellitus in patients with rheumatoid arthritis

Kostoglou-Athanassiou Ifigenia , Tzanavari Aikaterini , Banti Theodota , Katsavouni Charoula , Kalaycheva Natalia , Athanassiou Panagiotis

Introduction: In rheumatoid arthritis (RA) glucose metabolism may be affected either by the autoimmune inflammatory disease itself, or by the treatment used to manage the disease. Metabolic syndrome seems to be prevalent in RA patients.Aim: The aim was to study the prevalence of diabetes mellitus type 2 and metabolic factors related to the development of atherosclerosis within a cohort of RA patients cared for within a single Rheumatology Department....

ea0032p199 | Cardiovascular Endocrinology &amp; Lipid Metabolism | ECE2013

Lipid levels in patients with rheumatoid arthritis and the effect of rituximab

Kostoglou-Athanassiou Ifigenia , Xanthakou Eleni , Tzanavari Aikaterini , Gkountouvas Anastasios , Dadiras Nicolaos , Koutsika Eirini , Athanassiou Panagiotis

Rheumatoid arthritis (RA) is known to be associated with cardiovascular comorbidity. In particular, patients with RA are known to be at increased for the development of atherosclerosis. Treatment with biological agents in RA may affect lipid levels.Aim: The aim was to study the effect of rituximab treatment on lipid levels in RA patients.Methods: In a cohort of 20 patients with RA lipid levels were studied before, 6 and 12 months a...

ea0070ep130 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Similar effect of tocilizumab, an interleukin-6 receptor antagonist, administered either intravenously or subcutaneously on lipid levels in rheumatoid arthritis

Athanassiou Panagiotis , Athanassiou Lambros , Tzanavari Aikaterini , Gatsiou Marina , Devetzi Eirini , Tsakiridis Pavlos , Mavroudi Maria , Kostoglou-Athanassiou Ifigenia

Tocilizumab is an interleukin-6 receptor antagonist used in the treatment of rheumatoid arthritis (RA). It is known to induce remission and inhibit radiographic progression in RA. Tocilizumab may be administered either intravenously or subcutaneously. Its effect on lipid levels and the cardiovascular risk has not been fully investigated. The aim was to study the effect of tocilizumab administered either iv or sc on disease activity, lipid levels and cardiovascular risk in RA p...